361 related articles for article (PubMed ID: 23053143)
1. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity.
Alongi F; Fogliata A; Navarria P; Tozzi A; Mancosu P; Lobefalo F; Reggiori G; Clivio A; Cozzi L; Scorsetti M
Strahlenther Onkol; 2012 Nov; 188(11):990-6. PubMed ID: 23053143
[TBL] [Abstract][Full Text] [Related]
2. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
[TBL] [Abstract][Full Text] [Related]
3. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.
Di Muzio N; Fiorino C; Cozzarini C; Alongi F; Broggi S; Mangili P; Guazzoni G; Valdagni R; Calandrino R; Fazio F
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):392-8. PubMed ID: 19056184
[TBL] [Abstract][Full Text] [Related]
5. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP
Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.
Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M
Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027
[TBL] [Abstract][Full Text] [Related]
8. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
9. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
[TBL] [Abstract][Full Text] [Related]
10. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.
Lopez Guerra JL; Isa N; Matute R; Russo M; Puebla F; Kim MM; Sanchez-Reyes A; Beltran C; Jaen J; Bourgier C; Marsiglia H
Clin Transl Oncol; 2013 Apr; 15(4):271-7. PubMed ID: 22855189
[TBL] [Abstract][Full Text] [Related]
14. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience.
Hegazy MW; Mahmood RI; Al Otaibi MF; Khalil EM
J Egypt Natl Canc Inst; 2016 Jun; 28(2):101-10. PubMed ID: 27133975
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity.
Valeriani M; Carnevale A; Osti MF; Minniti G; De Sanctis V; Agolli L; Bracci S; Enrici RM
Tumori; 2013; 99(4):474-9. PubMed ID: 24326835
[TBL] [Abstract][Full Text] [Related]
17. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.
Michalski JM; Yan Y; Watkins-Bruner D; Bosch WR; Winter K; Galvin JM; Bahary JP; Morton GC; Parliament MB; Sandler HM
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):932-8. PubMed ID: 24113055
[TBL] [Abstract][Full Text] [Related]
18. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
19. Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.
Guckenberger M; Ok S; Polat B; Sweeney RA; Flentje M
Strahlenther Onkol; 2010 Oct; 186(10):535-43. PubMed ID: 20890743
[TBL] [Abstract][Full Text] [Related]
20. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
